Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer

Open access
Fackler, Mary Jo, Lopez Bujanda, Zoila, Umbricht, Christopher, Teo, Wei Wen, Cho, Soonweng, Zhang, Zhe, Visvanathan, Kala, Jeter, Stacie, Argani, Pedram, Wang, Chenguang, Lyman, Jaclyn P., de Brot, Marina, Ingle, James N., Boughey, Judy, McGuire, Kandace, King, Tari A., Carey, Lisa A., Cope, Leslie, Wolff, Antonio C., Sukumar, Saraswati · 2014 · Cancer Research

Abstract

The ability to consistently detect cell-free tumor-specific DNA in peripheral blood of patients with metastatic breast cancer provides the opportunity to detect changes in tumor burden and to monitor response to treatment. We developed cMethDNA, a quantitative multiplexed methylation-specific PCR assay for a panel of ten genes, consisting of novel and known breast cancer hypermethylated markers identified by mining our previously reported study of DNA methylation patterns in breast tissue (103 cancer, 21 normal on the Illumina HumanMethylation27 Beadchip) and then validating the 10-gene panel in The Cancer Genome Atlas project breast cancer methylome database. For cMethDNA, a fixed physiologic level (50 copies) of artificially constructed, standard nonhuman reference DNA specific for each gene is introduced in a constant volume of serum (300 μL) before purification of the DNA, facilitating a sensitive, specific, robust, and quantitative assay of tumor DNA, with broad dynamic range. Cancer-specific methylated DNA was detected in training (28 normal, 24 cancer) and test (27 normal, 33 cancer) sets of recurrent stage IV patient sera with a sensitivity of 91% and a specificity of 96% in the test set. In a pilot study, cMethDNA assay faithfully reflected patient response to chemotherapy (N = 29). A core methylation signature present in the primary breast cancer was retained in serum and metastatic tissues collected at autopsy two to 11 years after diagnosis of the disease. Together, our data suggest that the cMethDNA assay can detect advanced breast cancer, and monitor tumor burden and treatment response in women with metastatic breast cancer. Cancer Res; 74(8); 2160–70. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-3392

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 170

Metadata

Authors
Fackler, M. J., Lopez Bujanda, Z., Umbricht, C., Teo, W. W., Cho, S., Zhang, Z., Visvanathan, K., Jeter, S., Argani, P., Wang, C., Lyman, J. P., de Brot, M., Ingle, J. N., Boughey, J., McGuire, K., King, T. A., Carey, L. A., Cope, L., Wolff, A. C., & Sukumar, S.
Venue
Cancer Research
Published
2014-04-15
Volume
74
Issue
8
Pages
2160-2170
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2165880784
Cited by
170
References
1
FWCI
6.03
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-3392
The paper
Fackler, M. J., Lopez Bujanda, Z., Umbricht, C., Teo, W. W., Cho, S., Zhang, Z., Visvanathan, K., Jeter, S., Argani, P., Wang, C., Lyman, J. P., de Brot, M., Ingle, J. N., Boughey, J., McGuire, K., King, T. A., Carey, L. A., Cope, L., Wolff, A. C., & Sukumar, S. (2014). Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-3392

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.